Zynerba reports positive Phase II trial results for transdermal CBD gel ZYNOO2 in Fragile X syndrome
Zynerba reports positive Phase II trial results for transdermal CBD gel ZYNOO2 in Fragile X syndrome The passage only contains internal trial data on a biotech company's cannabinoid product, with no mention of high‑profile officials, financial flows, or controversial actions. It offers no actionable leads for investigations into powerful actors. Key insights: GW and Zynerba are conducting cannabinoid trials for autism, epilepsy, and Fragile X syndrome.; Zynerba's Phase II open‑label study showed statistically significant improvements on ADAMS scores.; Adverse events were mild; no serious adverse events reported.
Summary
Zynerba reports positive Phase II trial results for transdermal CBD gel ZYNOO2 in Fragile X syndrome The passage only contains internal trial data on a biotech company's cannabinoid product, with no mention of high‑profile officials, financial flows, or controversial actions. It offers no actionable leads for investigations into powerful actors. Key insights: GW and Zynerba are conducting cannabinoid trials for autism, epilepsy, and Fragile X syndrome.; Zynerba's Phase II open‑label study showed statistically significant improvements on ADAMS scores.; Adverse events were mild; no serious adverse events reported.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.